**Introduction to Stem Cell Therapy**
For 25 years, researchers have made ambitious claims about stem cells transforming medicine. These extraordinary cells, first extracted from human embryos in the late 1990s, have an exceptional capability: they can theoretically evolve into any tissue within the human body. The concept was enticing—imagine having spare parts available for any bodily failure. However, the path from laboratory expectation to clinical reality has proven to be much more difficult than expected.
The industry went through years of exaggeration, disillusionment, and even exploitation by unethical clinics. However, after decades of meticulous research, stem cell therapy is at last fulfilling its groundbreaking promise. Two pioneering treatments for epilepsy and type 1 diabetes are yielding impressive results that are altering patients’ lives.
**How Stem Cell Therapy Works**
Stem cell therapy utilizes the inherent potential of these adaptable cells to transform into specialized tissues. Researchers employ either embryonic stem cells or iPSCs (adult cells reprogrammed to function like embryonic cells). By implementing stringently controlled laboratory conditions, they direct these stem cells to specialize into particular cell types essential for treatment.
For epilepsy treatment, stem cells become specialized neurons that generate GABA, a neurotransmitter that helps soothe excessive brain signals. For diabetes therapy, stem cells evolve into beta islet cells—the insulin-producing cells typically found in the pancreas but destroyed in patients with type 1 diabetes.
Once developed, these laboratory-engineered cells are transplanted into patients. The transplanted cells then merge with existing tissues and commence their intended functions. The aim is a “functional cure” where the patient’s body can self-regulate without the need for constant medical treatment.
**Breakthrough Treatment for Epilepsy: Justin Graves’ Story**
Justin Graves was running a scuba diving business in Louisville, Kentucky, when epilepsy suddenly disrupted his life. At 22, he was diagnosed with temporal lobe epilepsy. The condition took everything—federal regulations disallow anyone with a history of seizures from scuba diving, terminating his career. He couldn’t drive, requiring him to relocate and accept any available jobs along bus routes.
By 2023, now 39 and two-and-a-half years sober, Graves was having one to two seizures every day. When his doctors at UC San Diego proposed an experimental stem cell treatment, he readily consented. The therapy, known as NRTX-1001 and developed by Neurona Therapeutics, involved injecting thousands of lab-grown neurons directly into his brain.
In July 2023, neurosurgeon Dr. Sharona Ben-Haim guided a ceramic needle into his hippocampus and delivered thousands of inhibitory interneurons cultivated from stem cells. These specialized cells release GABA, which could potentially reduce the electrical storms that trigger epileptic seizures.
The outcomes surpassed expectations. Within weeks, Graves observed a significant decline in his seizures. By early 2025, he was having seizures only about once a week, down from daily episodes prior to treatment. Other patients reported similar achievements—one woman in Oregon experienced an eight-month period without a seizure. Of the first five volunteers treated, four noted reductions in seizure frequency of eighty percent or more. Patients also demonstrated cognitive enhancements, especially in memory.
For Dr. Ben-Haim, this signifies a potential shift in paradigm. Traditional surgical methods involve excising or damaging problematic brain tissue, coming with severe risks including memory loss and vision deterioration. Providing a definitive treatment without damaging brain matter could transform epilepsy management.
**Revolutionary Diabetes Treatment: A Functional Cure**
Type 1 diabetes is an autoimmune disorder where the body eliminates insulin-producing beta cells in the pancreas. In the absence of these cells, patients are unable to control blood sugar and must depend on constant monitoring and multiple daily insulin injections to survive.
In June 2024, Vertex Pharmaceuticals announced astonishing results. Twelve individuals with type 1 diabetes who underwent an experimental stem cell therapy named VX-880 (later rebranded as zimislecel) were producing sufficient insulin to maintain healthy blood glucose levels ninety days after a single treatment. Most remarkably, three patients followed for an entire year no longer required insulin injections at all.
The therapy entails differentiating stem cells into functional beta islet cells and then administering them through a single infusion. All twelve patients who received the complete dose met the recommended blood sugar targets and sustained healthy glucose levels. Their bodies could now self-regulate in a manner they hadn’t been able to since their diagnosis.
This indicates a “functional cure.” Patients must take immunosuppressant medications to prevent rejection and need continuous monitoring, but for many, the change has been transformative. No longer will they face constant blood sugar tests, no longer do they have to calculate insulin doses with each meal, no longer will they live in fear of severe hypoglycemic events during sleep. Vertex has initiated pivotal trials as of July 2025, advancing towards potential FDA approval.
The trial was briefly paused in January 2024 after two participants passed away, though neither death was thought to be connected to the treatment itself. These incidents highlight the stringent safety monitoring necessary in pioneering research, but